Bioniche Pharma Ltd. Launches Ibutilide Fumarate Injection
Published: Jan 12, 2010
LAKE FOREST, Ill., Jan. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert(R) from Pfizer Inc.
"The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George Zorich, President, US Operations for Bioniche Pharma.
This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please refer to the Bioniche Pharma website at www.bionichepharma.com for the complete prescribing information for this product, including the boxed warning.
Corvert(R) is a registered trademark of Pharmacia & Upjohn Company LLC
CONTACT: Kara Maxwell of Bioniche Pharma, +1-847-739-3249,
Web site: http://www.bionichepharma.com/